The Neuroprotective Effects of Heat Shock Protein 27 Overexpression in Transgenic Animals against Kainate-induced Seizures and Hippocampal Cell Death*

Mohammed T. Akbar {ddagger}, Anna M. C. Lundberg {ddagger}, Ke Liu {ddagger}, Sharmili Vidyadaran {ddagger}, Kim E. Wells {ddagger}, Hamid Dolatshad {ddagger}, Sarah Wynn {ddagger}, Dominic J. Wells {ddagger}, David S. Latchman § and Jacqueline de Belleroche {ddagger} 

From the {ddagger}Department of Neuromuscular Diseases, Division of Neuroscience and Psychological Medicine, Faculty of Medicine, Imperial College, London, Fulham Palace Road, London W6 8RF, United Kingdom and the §Institute of Child Health, UCL, Guilford Street, London WC1N 1EH, United Kingdom

Received for publication, July 15, 2002 , and in revised form, March 10, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The 27-kDa heat shock protein (HSP27) has a potent ability to increase cell survival in response to a wide range of cellular challenges. In order to investigate the mode of action of HSP27 in vivo, we have developed transgenic lines, which express human HSP27 at high levels throughout the brain, spinal cord, and other tissues. In view of the particular property of HSP27 compared with other HSPs to protect neurons against apoptosis, we have tested these transgenic lines in a well established in vivo model of neurotoxicity produced by kainic acid, where apoptotic cell death occurs. Our results demonstrate for the first time the marked protective effects of HSP27 overexpression in vivo, which significantly reduces kainate-induced seizure severity and mortality rate (>50%) in two independent lines and markedly reduces neuronal cell death in the CA3 region of hippocampus. This reduced seizure severity in HSP27 transgenic animals was associated with a marked attenuation of caspase 3 induction and apoptotic features. These studies clearly demonstrate that HSP27 has a major neuroprotective effect in the central nervous system in keeping with its properties demonstrated in culture and highlight an early stage in the cell death pathway that is affected by HSP27.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The heat shock proteins (HSPs)1 are a family of proteins originally identified as being up-regulated in response to elevated temperature, but now a wide range of cellular stresses such as hypoxia, ischemia, glutamate, and heavy metals have been shown to induce HSPs (1, 2, 3, 4, 5, 6). HSPs consist of a family of highly conserved proteins grouped according to their molecular size: the high molecular mass proteins (110, 90, 70–72, and 55–60 kDa) and the small HSPs, which include HSP27, ubiquitin, {alpha}A- and {alpha}B-crystallin, and related species. Although highly conserved across species, variation in protein size occurs; for example, the 27-kDa human HSP27 has a corresponding isoform of 25 kDa in rodents referred to as HSP25. HSPs are both constitutively expressed and induced in response to stressful stimuli (e.g. HSP27 and HSP70). Rapid induction of HSP expression is mediated by specific heat shock factors (heat shock factors 1–4), which regulate transcription (7).

The HSPs play a key role in cellular defense systems, acting as protein chaperones facilitating protein folding and the removal of aberrant proteins. These properties have been shown to contribute to the enhanced cellular survival produced following preconditioning stimuli in which a subthreshold stimulus is used to raise endogenous heat shock protein levels prior to the main stimulus. Primary neuronal cultures are protected by prior exposure to mild heat or ischemic stress before subsequent more severe heat or ischemic stress or exposure to glutamate (8, 9, 10). In cardiac tissue, a mild heat shock also protects against a subsequent thermal or ischemic stress (11).

The effects of heat shock can be mimicked by overexpression of HSPs alone. Both the ND7 immortalized neuronal cell line, which is derived from dorsal root ganglia neurons, and primary cultures of dorsal root ganglion neurons can be protected against subsequent ischemic or thermal stress by overexpression of HSP70 (12, 13, 14, 15) or HSP90 (90-kDa HSP) (13, 15). In cardiac cells or primary cultures of cardiac cells, overexpression of HSP70 protects against subsequent thermal or ischemic stress (16, 17, 18), but HSP90 only protects against thermal stress and does not protect against ischemic stress.

Marked differences are seen for each HSP in their tissue and cellular specificity and their response to different insults. For example, seizure activity is associated with a rapid HSP70 induction in hippocampal neuronal populations, whereas HSP27 induction is primarily in glial cells and of longer duration (19). Similarly, whereas prior heat shock protects ND7 neuronal cells and primary neurons against apoptosis due to withdrawal of serum or neural growth factor (13, 20), overexpression of HSP70 or HSP90 is not protective. Overexpression of HSP27 in ND7 neuronal cell lines does, however, protect not only against subsequent exposure to heat shock and simulated ischemia but most importantly to stimulation of apoptosis by serum withdrawal in the presence of all-trans-retinoic acid (21). Similarly, in primary dorsal root ganglion cells, infection with herpes simplex virus vectors expressing HSP27 or HSP70 protects against heat shock and simulated ischemia, whereas only expression of HSP27 protects against apoptosis induced by neural growth factor withdrawal (21). HSP27 also reduces the extent of apoptosis in monocytic cells exposed to DNA-damaging agents (22) and fibrosarcoma cells exposed to Fas-induced apoptosis or staurosporine (23). Overexpression of HSP27 in cardiac myocytes using an adenovirus vector also protects against simulated ischemia (24). Infection of neonatal cardiac cells using an HSP27-expressing herpes simplex virus vector not only protects cells against heat shock and ischemia but also minimizes the extent of apoptosis induced by serum withdrawal or treatment with ceramide (25).

Through our previous studies, we were thus able to show that transfection with HSP27 conferred protection against apoptosis in neuronal cells, which was not evident with HSP70, although both HSPs were protective against heat shock and hypoxia. This finding prompted us to develop transgenic mouse lines overexpressing the human HSP27 (hHSP27) gene in order to determine whether evidence could be obtained in vivo for protection against apoptotic and ischemic insults in CNS. No such transgenic mouse has been previously reported for HSP27, although transgenic mice overexpressing HSP70 have been generated. Studies of cerebral ischemia using HSP70 transgenic lines have not yielded consistent results; whereas some authors have shown reduced cerebral infarcts (26), others do not show reduced infarct size following permanent cerebral focal ischemia (27). This may be due to background strain differences and/or differences in expression levels, since different promoters were used in these studies (28).

In order to carry out further elucidation of the neuroprotective properties of HSP27 and to determine whether in vivo protection can be demonstrated by HSP27, we generated transgenic mouse lines in which wild-type hHSP27 was expressed at high levels in cardiac and CNS tissue. Three independent lines were generated in order to confirm that protective effects could be replicated and to ensure that the effect was due to the HSP itself rather than due to the particular site of integration. These independent transgenic lines were then tested in the CNS using the in vivo administration of kainic acid to induce seizures and hippocampal cell death. All transgenic lines showed abundant hHSP27 expression throughout the brain, with particularly high expression levels in all hippocampal subfields. The kainic acid model is a well established experimental model of temporal lobe epilepsy in which systemic kainic acid results in sustained seizures followed by a selective pattern of neuronal damage in vulnerable limbic structures, most notably the CA3 region of hippocampus (29, 30). Although the mode of cell death includes both apoptotic and necrotic components, it provides a useful model to induce apoptotic cell death in vivo (31, 32, 33, 34).

The results obtained show that HSP27 plays an important role in CNS neuroprotection, as predicted from earlier cell culture studies, and in addition provide a preliminary insight into the site of action of HSP27 in vivo in the cell death cascade through its effects on caspase 3 induction.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Establishment of Transgenic Mouse Lines Expressing Human HSP27—Transgenic mice were created using a transgene containing human HSP27 cDNA with a chicken {beta}-actin promotor and cytomegalovirus enhancer (pCAGGS) (35). In order to track expression of the transgene, a hemagglutinin (HA) tag was placed contiguous with the HSP27 cDNA sequence. The linearized transgene was microinjected into pronuclei of fertilized eggs from C57BL10 x CBA/Ca mice, which were subsequently transferred to pseudopregnant recipients. This procedure was carried out in the Imperial College Gene Targeting Unit. At 3–4 weeks after birth, a small tail biopsy was taken from pups, and genomic DNA screened for the integration of the transgene using PCR. Founders revealed by this screening were used to establish independent transgenic lines by breeding to wild-type F1 hybrid (C57BL10 x CBA/Ca) mice. Following successful transmission, a range of tissues were screened by Western blot and immunohistochemistry to confirm CNS and cardiac expression. Overexpression of human HSP27 did not appear to produce any obvious effects on development or survival in mice from all three lines generated. Histological comparisons of brain and cardiac tissue from the different mouse lines revealed no observable morphological differences when compared with corresponding tissue from their respective wild-type littermates, although no detailed (quantitative) studies were carried out as a part of this study.

Experimental Model of in Vivo Apoptosis Using Kainate—Mice were injected intraperitoneally with kainic acid (KA; Tocris) (20–30 mg/kg) or vehicle (phosphate-buffered saline (PBS); 1 ml/kg). For dose-response studies, the following kainate doses were used with wild-type (WT) mice: 20 mg/kg, n = 18; 25 mg/kg, n = 39; 30 mg/kg, n = 4. A dose of 25 mg/kg was chosen for behavioral studies, since it produced the most consistent response (hHSP27(18), n = 35; WT, n = 39; hHSP27(64), n = 30; WT, n = 25). Animals were monitored continuously for 4 h for the onset and extent of seizure activity. The seizures were scored using a modified scale devised by Racine (36): 1, behavioral arrest, staring spells; 2, head bobbing, gnawing; 3, unilateral forelimb clonus; 4, bilateral forelimb clonus; 5, severe seizures with loss of postural control; 6, seizure-induced death. Animal care and procedures carried out followed Home Office guidelines and an ethical review committee-approved protocol.

For in situ hybridization studies, animals were killed at 24 h after KA or vehicle or were untreated. Brains were rapidly removed and frozen on dry ice. Sections were cut (10 µm) on a cryostat (Bright Instruments), thaw-mounted onto Superfrost slides (BDH), and stored at –80 °C until use. For histology and neuron counts, animals were killed at 7 days after kainate injection (hHSP27(18), n = 6; WT, n = 6) or vehicle (hHSP27(18), n = 7; WT, n = 3), and brains were removed and processed as above.

In Situ Hybridization—Specific antisense oligonucleotides were synthesized (Sigma-Genosys Ltd.) for use in the in situ hybridization studies. For detection of hemagglutinin tag mRNA, a 27-mer oligonucleotide, 5'-agcgtaatctggaacatcgtatgggta-3' was used. For detection of human HSP27 mRNA, two probes (A and B) were used, which were based on the human HSP27 sequence (37). Probe A is a 33-mer oligonucleotide complementary to nucleotides 540–572, and probe B is a 33-mer oligonucleotide complementary to nucleotides 593–625. Both human HSP27 probes and the hemagglutinin tag probe yielded identical patterns of expression. For mouse HSP25 mRNA, three probes (probes 1, 2, and 3) were used, which are based on the mouse HSP25 sequence (38). Probe 1 is a 34-mer oligonucleotide complementary to nucleotides 358–391, probe 2 is a 33-mer oligonucleotide complementary to nucleotides 497–529, and probe 3 is complementary to nucleotides 550–582. All three HSP25 probes yielded identical patterns of expression. For mouse glial fibrillary acidic protein (GFAP) mRNA, a 45-mer oligonucleotide complementary to nucleotides 1119–1163 of the mouse GFAP gene (39) was used. For detection of caspase 3 (mouse CPP32) mRNA, three probes (A, B, and C) were used, which were based on the mouse CPP32 gene sequence (40). Probe A is a 32-mer oligonucleotide complementary to nucleotides 577–608, probe B is a 31-mer oligonucleotide complementary to nucleotides 115–145, and probe C is a 32-mer oligonucleotide complementary to nucleotides 147–176. These probes gave similar distribution patterns. The data presented in this paper have been obtained using probe A. Oligonucleotide probes were 3' end-labeled using terminal deoxynucleotidyl transferase (Promega) and [35S]dATP (Amersham Biosciences).

Cryostat sections were processed, and in situ hybridization was carried out as previously described (19). In brief, slides were fixed in 4% paraformaldehyde in PBS (4 °C) for 10 min, rinsed in PBS for 2 x 5 min, and then treated with 0.25% acetic anhydride in 0.1 M triethanolamine, 0.9% NaCl for 10 min. Following dehydration in increasing concentrations of ethanol, the sections were delipidated in chloroform for 5 min, rinsed in ethanol, and allowed to air-dry. Sections were then hybridized overnight at 42 °C with 1–2 x 106 cpm of labeled probe in 100 µl of hybridization buffer (5x Denhardt's solution (0.02% bovine serum albumin, 0.02% Ficoll, and 0.02% polyvinylpyrrolidone), 4x standard saline citrate (SSC), 50% formamide, 10% dextran sulfate, 200 µg/ml polyadenylic acid, 200 µg/ml sheared single-stranded salmon sperm DNA, 50 mM phosphate buffer, and 20 mM dithiothreitol). The following day, sections were stringently washed (1x SSC at room temperature for 30 min, 1x SSC at 55 °C for 30 min, 0.5x SSC at 55 °C for 30 min, 0.1x SSC at 55 °C for 30 min, and 0.1x SSC at room temperature), dehydrated in an ascending series of ethanols, and air-dried. When dry, sections were exposed to x-ray film (BioMax MR; Eastman Kodak Co.) for 7–14 days and developed. Sections were then dipped in photographic emulsion (Ilford K5) and exposed for 1–6 weeks at 4 °C, developed, and counterstained with toluidine blue for light microscopic analyses.

Semiquantitative Analysis of Caspase 3 mRNA—The semiquantitative analysis of signal intensity in the CA3 region of the hippocampus was carried out by assigning a score in the range of 0–3 (0 = no signal, 1 = low signal, 2 = moderate signal, and 3 = maximum signal intensity obtained). All sections were hybridized, exposed to autoradiographic film, and developed together in the same experiment. Scoring of sections was carried out by three observers without knowledge of the treatment. There was good agreement of scores, and where differences occurred, a mean of scores was taken. Group scores were analyzed using the Mann-Whitney U test (InStat version 2.01).

Analysis of Neuronal Cell Density in Hippocampus—Serial coronal sections of the brain were cut at 10 µm, stained with hematoxylin-eosin, dehydrated through a series of alcohols, cleared in xylene, and cover-slipped. Histological analysis of cell morphology and cell counts in the hippocampus were confined to approximately –1.94 to –2.46 mm posterior to bregma (41). The Nikon Eclipse E800 microscope used for this study was equipped with a motor-driven stage to traverse the x and y axes. To define the boundaries of the hippocampus, slides were viewed with a x10 objective. The entire hippocampus was then captured by a JVC 3-CCD color video camera, and the image was tiled onto a color monitor screen. A geometrical area of interest (0.036 mm2) was placed in the CA1 and CA3 regions of the hippocampus. This procedure was standardized in order to sample the same areas of these regions. Digital images were analyzed by the Image-Pro Plus 4.1 program (Data Cell). Morphological criteria of the normal pyramidal cells were established in the control mice based on size (length) and cellular staining. To prevent counting glial cells and degenerating neurons, all counting was thresholded at a minimal cell length of 0.009 pixels. The mean neuron count was obtained from three sections per animal. Cell counts were averaged, and neuronal cell density was expressed in terms of morphologically normal nuclei per square field of 0.036 mm2. Differences in neuronal cell densities between all of the treatment groups were assessed using the Kruskal-Wallis nonparametric analysis of variance test followed by Mann-Whitney U test (InStat version 2.01).

Western Blot Analysis—Tissues were snap-frozen in liquid nitrogen, and protein was extracted directly by homogenization in SDS sample buffer containing 10% SDS and a mixture of protease inhibitors. When quantification of protein concentration was required, the samples were homogenized in reporter gene assay lysis buffer (Roche Applied Science) plus protease inhibitors to give a final protein concentration of 100 mg/ml based on tissue wet weight. Protein concentration was determined using the detergent-compatible protein assay (Bio-Rad). For protein gels, 100 µg of total protein was then further solubilized in 20 µl of 10% SDS sample buffer for each gel track. Proteins were separated on 10–20% acrylamide gradient Tris-glycine gels (Bio-Rad) and transferred onto polyvinylidene difluoride membranes (Amersham Biosciences) for 1 h at 100 V. Membranes were then air-dried. The efficiency of protein transfer was assessed by staining the membrane with 1% Amido Black in 10% methanol plus 10% acetic acid, destaining, and washing in Tris-buffered saline, pH 8, 0.05% Tween 20 (TBST). Nonspecific binding was blocked using a 5% solution of dried milk powder (Marvel) in TBST. Western blot analysis was carried out using an antibody directed against the HA tag at 1:500 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), blotting grade anti-rabbit horseradish peroxidase conjugate (Bio-Rad) at 1:10,000, and detection with ECL reagent (Amersham Biosciences) using blue light-sensitive x-ray film. Three 5-min washes with TBST were performed between each antibody step.

Immunocytochemistry—Brain and heart samples were mounted on cork discs using Cryo-M-Bed (Bright) and frozen in liquid nitrogen-cooled isopentane. 10-µm cryosections were cut, mounted on glass slides, air-dried and stored at –70 °C. Prior to staining sections were air-dried and fixed for 20 min at room temperature in 4% formalin. Endogenous peroxidase activity was blocked by treating sections with 3% hydrogen peroxidase solution for 10 min followed by blocking for endogenous biotin using the avidin/biotin block as per the manufacturer's instructions (Dako). Nonspecific binding was blocked using 3% Marvel in TBST for 30 min followed by antibodies to either hHSP27 at 1:1000 (Stressgen) or the HA tag at 1:100 (Santa Cruz Biotechnology) for 30 min. Biotinylated anti-rabbit at 1:500 (Dako) was then followed by a streptavidin ABC-horseradish peroxidase complex (Dako) for 30 min each and visualization with hydrogen peroxide activated DAB. Three 5-min washes in TBST were carried out between each step. Tissue sections were counterstained with hematoxylin, dehydrated through graded alcohols, cleared with xylene, and mounted in DPX mountant (distrene, plasticiser, xylene).

Statistical Analysis—Seizure score data were analyzed by Mann-Whitney U test. Fisher's exact test was used to compare mortality rates. Significance level was set at 0.05 for all comparisons.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Establishment of Transgenic Mouse Lines Expressing Human HSP27—Three independent lines (lines 18, 59, and 64) of transgenic mice with similar patterns of expression of the human HSP27 transgene were generated. All three lines showed widespread expression in brain, spinal cord, heart, muscle, liver, kidney, lung, and pancreas. A similar high level of expression is shown in the brain for all three lines (Fig. 1A) by Western blot analysis, where equal amounts of protein were loaded and blots were probed with an antibody to the HA tag (Fig. 1A) or hHSP27 (data not shown). The widespread distribution of hHSP27 expression is shown for multiple tissues in Fig. 1B for hHSP27(18). A similar distribution was shown for hHSP27(59) and hHSP27(64) (data not shown). Antibodies to hHSP27 yielded identical results to antibodies directed to the HA tag on these Western blots (data not shown). All transgenic lines showed normal reproductive patterns and longevity, and behavior was not noticeably different from wild-type littermates.



View larger version (27K):
[in this window]
[in a new window]
 
FIG. 1.
Western blots showing expression of HA-tagged hHSP27 in three independent mouse lines. Western blots were probed with an antibody directed against the HA tag. A, whole brain homogenates from age-matched male mice were loaded at 100 µg of total protein per track. The wild type control animal was a nontransgenic littermate from line hHSP27(18). B, Western blot analysis of transgene expression in different regions of the brain and other tissues from hHSP27(18). Tracks labeled with a plus sign are transgenic animals, and tracks labeled with a minus sign are nontransgenic littermates. A similar distribution of expression was seen for both hHSP27(59) and hHSP27(64) (data not shown).

 

Transgene Expression in Brain—Immunocytochemistry was carried out on the three independent mouse lines expressing the transgene using the same two antibodies. Using the HA tag antibody, labeled neuronal cell bodies were detected throughout the brain, being particularly abundant in the hippocampus, cerebral cortex, cerebellum, striatum, thalamus, and subventricular nuclei. Extensive labeling of fibrous networks and small cells was also seen, suggesting expression in glial cells.

A similar distribution of expression of hHSP27 was seen for all three mouse lines (lines 18, 59, and 64). In CA1, CA3, and the hilus, cell bodies and their projections were strongly labeled, and extensive axonal and dendritic labeling was also seen in CA1 and CA3. This is shown for all 3 lines 18, 64, and 59 (Fig. 2, only shown for lines 18 and 64). In the dentate gyrus, transgene expression occurred in granule cells as well as the interneurons lining the internal surface of the granule cell layer, which were labeled using a GAD67 antibody in adjacent sections (data not shown).



View larger version (144K):
[in this window]
[in a new window]
 
FIG. 2.
Hippocampal expression of hHSP27 in two independent transgenic mouse lines used for behavioral studies. Immunohistochemistry was carried out using an antibody to the HA tag that is contiguous with hHSP27. The left panels show expression in CA1 (A–C), and the right panels show expression in the CA3 region of hippocampus (D–F) for wild-type (A and D), hHSP27(18) (B and E), and hHSP27(64) (C and F). The arrows indicate labeled cells, and arrowheads point to dendritic labeling. Scale bar, 20 µm.

 

Distribution of Expression of hHSP27 Transgene mRNA in Brain—The expression of the hHSP27 transgene in the three mouse lines showing CNS expression of HSP27 protein from Western blot and immunohistochemistry was also characterized by in situ hybridization. Two HSP27 oligonucleotide probes (probes A and B) directed against the human sequence and not reactive with mouse (37) were tested together with a probe for the HA tag sequence, which was contiguous with the HSP27 transgene. All three probes produced identical RNase A-sensitive patterns of expression in brain sections from unstressed hHSP27(18) mice, whereas no signal was detected in sections from unstressed and kainate-stressed wild-type mice (HSP27-probe B, data shown in Fig. 3, A–D; HSP27-probe A and HA tag probe, data not shown). Probe B was used for further characterization of CNS expression of the HSP27 transgene.



View larger version (151K):
[in this window]
[in a new window]
 
FIG. 3.
Expression of hHSP27 in transgenic animals. This expression is compared with the expression of mouse HSP25, which is not present in control animals but is detected in both wild-type and transgenic animals receiving an intraperitoneal injection of kainate, which produces a substantial induction of mouse HSP25. Shown are hHSP27 mRNA (A–D), mHSP25 mRNA (E–H), and GFAP mRNA (I–L) in horizontal brain sections from wild-type (A, C, E, G, I, and K) and hHSP27(18) (B, D, F, H, J, and L) mice killed 24 h after kainate (C, D, G, H, K, and L) or PBS (A, B, E, F, I, and J). hHSP27 mRNA is expressed exclusively in hHSP27(18) mice (B and D) and absent in PBS-treated (A) and kainate-treated (C) wild-type mice. mHSP25 mRNA is expressed specifically in kainate-injected mice (G and H). GFAP mRNA is up-regulated in kainate-injected mice (K and L). Scale bar, 2 mm.

 

To validate further the specificity of these probes for the HSP27 transgene, three additional probes (probes 1–3) directed to the endogenous inducible mouse HSP25 gene (38) were synthesized. All three probes (1, 2, and 3) yielded identical hybridization signals in brain sections from kainate-stressed hHSP27(18) and kainate-stressed wild-type mice that greatly contrasted with the hybridization pattern for the HSP27 transgene (probe 1 data shown in Fig. 3, G and H; probe 2 and 3 data not shown). Furthermore, the HSP25 mRNA signal was absent in mouse brain sections from unstressed hHSP27(18) mice (Fig. 3E), unstressed wild type mice (Fig. 3F), and RNase A-treated sections (data not shown), thus confirming the species specificity of the probes. Therefore, the transgenic mice clearly contain greatly elevated levels of HSP27 mRNA, which is present in the absence of stress.

In kainate-treated mice, HSP25 mRNA expression was induced intensely in thalamus, moderately in hippocampus and at low levels in the cerebral cortex (Fig. 3, G and H) being predominantly localized to glial cells (data not shown). Induction of HSP25 appeared to be similar in both control and transgenic animals, indicating no suppression of endogenous HSP25 induction by the transgene.

A molecular marker of brain injury in response to kainate, GFAP induction, was used to substantiate the behavioral response to kainate. GFAP mRNA expression was up-regulated following kainate administration to a similar extent in both wild-type and hHSP27(18) mice (Fig. 3, K and L) compared with PBS-treated control mice (Fig. 3, I and J). High expression of GFAP mRNA was seen in hippocampus, entorhinal cortex, and septal nuclei, whereas moderate to low levels were observed in corpus callosum and thalamus (Fig. 3, K and L).

Expression of hHSP27 mRNA was extensive throughout cerebral cortex, CA1 and CA3 of hippocampus, dentate gyrus, striatum, and some thalamic regions (e.g. ventro-posterior lateral and medial thalamic nuclei). Moderate levels of expression were seen in lateral and medial habenula nucleus, dorsal lateral geniculate, and lateral septal nucleus. Little expression was seen in white matter (Fig. 4). There was some variation in the level of expression between lines; for example, in line 18, expression was highly abundant in cerebral cortex, hippocampus, striatum, and cerebellum, whereas for lines 59 and 64, a moderate but more widespread expression was seen throughout the brain.



View larger version (134K):
[in this window]
[in a new window]
 
FIG. 4.
Representative in situ film autoradiographs showing expression of hHSP27 mRNA in horizontal (A–C) and coronal (D–F) sections from three independent mouse lines, hHSP27(18) (A and D), hHSP27(64) (B and E), and hHSP27(59) (C and F). There is widespread expression of hHSP27 mRNA throughout the brain. Note the intense signal for hHSP27 mRNA in dentate gyrus and CA1 to CA3 subfields of the hippocampus in all three hHSP27 mouse lines. The greatest variation in expression levels among the three lines appears to be in the thalamus, striatum, and cortex. dg, dentate gyrus; CA1, CA2, and CA3, respective hippocampal fields; EnCx, entorhinal cortex; PiCx, piriform cortex; Th, thalamus; cc, corpus callosum; St, striatum. Scale bar, 2 mm.

 

Cellular Labeling of hHSP27 mRNA—Analyses of emulsion-dipped sections at the light microscopic level revealed a predominantly neuronal expression for hHSP27 mRNA in the dentate granule cells, CA1, CA3 (Fig. 5, B and D), and hilar cells of the hippocampus, striatum (Fig. 6B), and cerebral cortex (Fig. 6D) in all three lines. Intense labeling was seen in Purkinje cells of the cerebellum (data not shown), and moderate glial labeling was observed in the corpus callosum (Fig. 6F) of all mice expressing the hHSP27 transgene. Small cells with the characteristic appearance of glial cells, which were positive for hHSP27, were also seen in hippocampal regions (data not shown).



View larger version (63K):
[in this window]
[in a new window]
 
FIG. 5.
Bright field photomicrographs of the CA3 region of the hippocampus of wild-type (A), hHSP27(18) (B), and hHSP27(64) (C) mice showing mRNA expression of the hHSP27 transgene. Strong labeling is seen over pyramidal cells of the CA3 region in sections from both mouse lines (B, C). hHSP27 mRNA was not detected in CA3 cells in wild-type (Wt) mouse sections (A). Scale bar, 20 µm.

 


View larger version (103K):
[in this window]
[in a new window]
 
FIG. 6.
Cellular localization of hHSP27 mRNA in striatum (A and B), cortex (C and D), and corpus callosum (E and F) in sections from WT mice (A, C, and E), hHSP27(18) mice (B and F), and hHSP27(64) mice (D). hHSP27 mRNA is abundant in striatum (B) and cortex (D) of hHSP27 transgenic mice. Note the moderate labeling of glial cells in corpus callosum (arrows in F) in sections from mice expressing the hHSP27 transgene. Sections from WT mice do not show hHSP27 mRNA labeling. Scale bar, 20 µm.

 

Behavioral Effects of Kainate Administered Intraperitoneally—For the present study, we have concentrated on a single dose of kainate (25 mg/kg, intraperitoneally) that produces a consistent and maximal effect in our hands. Higher doses increase the mortality rate, and lower doses (20 mg/kg or lower) are less consistent, with fewer animals developing seizures (Fig. 7, inset). Animals were observed for 4 h following kainate administration to allow an evaluation of short term effects of epileptogenesis and seizure activity, and tissue was examined at 24 h and 7 days to characterize gene expression and to investigate morphological effects of cell death, respectively. Wild-type animals injected with kainate exhibited behavioral abnormalities as early as 15 min after administration of kainate, notably behavioral arrest and staring spells. This was followed by facial clonus and masticatory seizures within 30–60 min. Seizure behavior then progressed to forelimb clonus, rearing, and loss of balance within 1–2 h after injection with kainate. Most animals developed status epilepticus, but this varied in duration. In some animals, brief episodes (1–2 min) of generalized tonic-clonic seizures were observed. This behavioral profile in response to kainate injection is consistent with previous studies in mice (42, 43, 44, 45, 46).



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 7.
Time course of seizure severity in WT and hHSP27(18) mice following KA (25 mg/kg, intraperitoneal). The maximal seizure score achieved during 30-min intervals was recorded for each animal over a period of 4 h, and the mean seizure score for each group (WT or hHSP27 (18)) was plotted against time after kainate injection. Seizure scores are significantly reduced in hHSP27(18) mice at 60–180 min after KA compared with WT mice. Inset, dose response to kainate (20 mg/kg, n = 18; 25 mg/kg, n = 39; 30 mg/kg, n = 4) in WT mice. Data points beyond 150 min for the 30 mg/kg group are not shown due to the high mortality rate at this dose. Data were analyzed using nonparametric statistics (*, p < 0.05; **, p < 0.01; ***, p < 0.005; Mann Whitney U test). Data are shown as mean ± S.E. for ease of presentation. Seizure severity scores are described under "Experimental Procedures."

 

The time course of response to kainate injection (intraperitoneally) was markedly different in transgenic animals; hHSP27(18) mice overall exhibited much milder seizures throughout most of the 4-h observation period following kainate administration (Fig. 7). Further analysis showed that mean seizure scores were significantly reduced in kainate-treated hHSP27(18) mice at 60 min (p < 0.01), 90 min (p < 0.05), 120 min (p < 0.005), 150 min (p < 0.005), and 180 min (p < 0.05) compared with wild-type animals (Mann-Whitney U test) (Fig. 7). Seizure scores for a second transgenic line, hHSP27(64) mice, were analyzed in two separate experiments and were also shown to be significantly lower than wild-type mice following kainate injection (p < 0.05), and there appeared to be a delay in time to maximum seizure in hHSP27(64) mice, but this property did not reach statistical significance (data not shown). No significant behavioral changes were observed in vehicle-treated animals.

hHSP27 overexpression also had a significant effect on reducing mortality in the two independent lines tested. The mortality rate for hHSP27(18) mice was 18.4%, and the rate for hHSP27(64) mice was 16% after kainate treatment, which was significantly reduced compared with wild-type littermates (38.5%, p < 0.05; 40%, p < 0.05, respectively, by Fisher's exact test).

Cell Morphology following Kainate Administration—Typical morphological changes were seen at the light microscopic level following kainate administration (intraperitoneally), which included pyramidal cell loss in CA3 of the hippocampus with the appearance of vacuoles, atrophic changes, cell shrinkage, and chromatin condensation. These effects were seen in kainate-treated wild-type animals but were much reduced in the kainate-treated transgenic line (Fig. 8). The CA3 region showed signs of neuronal degeneration, with some of the neurons exhibiting eosinophilic cytoplasm and basophilic chromatin clumping (Fig. 9, C and E). These features are characteristic of the light microscopy appearance of apoptotic neurons, although no attempt was made to confirm this type of cell death. There were also signs of perineuronal vacuolation, evident in sections from all kainate-treated mice (Fig. 9, D–F).



View larger version (154K):
[in this window]
[in a new window]
 
FIG. 8.
Hemotoxylin-eosin-stained sections of the hippocampal CA3 pyramidal cell layer 7 days following vehicle (PBS) or kainic acid (25 mg/kg) administration (KA) to wild-type (Wt) or hHSP27(18) transgenic animals. Normal cell distribution in CA3 is evident in sections from WT-PBS (A), hHSP27(18)-PBS (B), and hHSP27(18)-KA (D) animals. Note the marked loss of pyramidal neurons in the CA3 region of the hippocampus in the KA-treated wild-type mice (C) but not in transgenic mice (D). Eosinophilic-stained neurons are present only in the kainate-treated wild-type mice (arrow in C). Scale bar, 50 µm. The inset shows zones (I–IV) within the hippocampus analyzed for cell counting. dg, dentate gyrus; CA1 and CA3, respective hippocampal fields.

 


View larger version (132K):
[in this window]
[in a new window]
 
FIG. 9.
High magnification of hemotoxylin-eosin-stained sections of the hippocampal CA3 pyramidal cell layer 7 days following vehicle (PBS) or kainic acid (25 mg/kg) administration (KA) to wild-type (Wt) and hHSP27(18) transgenic animals. High magnification sections (x400) of the CA3 subfields show the extent of degeneration in KA-treated wild type mice (C and E). Hemotoxylineosin staining clearly shows neurons with eosinophilic cytoplasm and large, round, basophilic clumps (an arrow points to three in C and four in E). There are also signs of perineuronal vacuolation in the KA-treated tissue (an arrowhead points to three in D, two in E, and three in F). Glial cells in D are indicated by asterisks. Scale bar, 20 µm.

 

Quantitative analysis of neuronal loss at 7 days following kainate injection was carried out by automated cell counting of hematoxylin-eosin stained sections in four zones within the CA1 and CA3 regions of the hippocampus in four animal groups: PBS-treated (n = 3) and KA-treated (n = 6) wild-type animals and PBS-treated (n = 7) and KA-treated (n = 6) transgenic animals (hHSP27) (18). Quantitative analysis of the neuronal cell density showed a significant loss of 33.1% (p < 0.05) in CA3 (zone III) in kainate-treated wild-type mice, but this was not significant in other regions analyzed (Fig. 10). There was no significant cell loss in CA1, in agreement with previous reports of kainate neurotoxicity in mice (47, 48). In kainate-treated transgenic animals, cell loss was much attenuated and was not significantly different from the respective vehicle-treated control group.



View larger version (40K):
[in this window]
[in a new window]
 
FIG. 10.
Neuronal cell density in the hippocampus of wild-type and hHSP27(18) transgenic mice following kainic acid (25 mg/kg KA) administration intraperitoneally. Histogram values (with S.E. shown by error bars) are means of neuronal cell density (cell number/mm2) in zones I–IV (defined in Fig. 9) of the hippocampus in wild-type animals treated with PBS vehicle (Wt-PBS; n = 3) or kainic acid (Wt-KA; n = 6) or transgenic animals treated with PBS (hHSP27(18)-PBS, n = 7) or kainic acid (hHSP27(18)-KA, n = 6). Cell loss was most marked in zone III of the WT animals treated with kainic acid compared with their PBS-treated controls. *, the value is significantly lower than the vehicle-treated control group (p < 0.05) (Kruskal-Wallis nonparametric analysis of variance test followed by Mann-Whitney U test).

 

Induction of Caspase 3 mRNA in Wild-type and Transgenic Animals—In order to obtain insight into the mechanism of action of HSP27 in vivo, the levels of caspase 3 mRNA were analyzed, which is known to be an early marker of the initiation of the apoptotic cell death cascade. This response is seen within a few hours of kainate administration, and two representative times of 4 and 8 h after kainate injection were examined. In parallel, the endogenous mouse HSP25 mRNA, which is also rapidly induced by kainate was investigated at 4 and 8 h after kainate injection. In wild-type animals, a prominent induction of caspase 3 was seen in CA3, CA1, and dentate gyrus at 4 h following kainate injection (Fig. 11, B, C, and D), which increased further in CA3 and CA1 at 8 h but decreased in dentate gyrus (Fig. 11, E–G). This effect was markedly attenuated in transgenic animals (hHSP27) (18) at both time points, being absent in most animals at 4 h after kainate injection (4 of 6; e.g. Fig. 11B1) or present at low to moderate levels in some (2 of 6; e.g. Fig. 11, C1 and D1). Similarly, at 8 h most transgenic animals showed little or no induction of caspase 3 (7 of 9; e.g. Fig. 11, E1 and F1) or moderate induction (2 of 9; e.g. Fig. 11G1).



View larger version (115K):
[in this window]
[in a new window]
 
FIG. 11.
Representative in situ film autoradiographs showing expression of caspase 3 mRNA and mouse HSP25 mRNA in hippocampus at 4 and 8 h after kainate injection. Expression of caspase 3 (CPP32) mRNA in wild-type (Wt) animals (A–G) and hHSP27(18) transgenic animals (A1–G1). Animals were treated with either PBS vehicle (A and A1) or kainate and assayed after either4h(B, C, D, B1, C1, and D1) or 8 h (E, F, G, E1, F1, and G1). Injection of kainate caused a highly specific induction of caspase 3 mRNA at 4 and 8 h in CA3, CA1, and dentate gyrus of hippocampus in wild-type animals (shown for three representative animals at each time point to demonstrate the range of the response obtained). In hHSP27(18) transgenic animals, the induction was either absent or much attenuated. No induction of caspase 3 was seen in PBS-treated animals. Similarly, expression of mHSP25 mRNA is shown for wild-type (H–N) and hHSP27(18) transgenic animals (H1N1) at 4 and 8 h after kainate injection. Virtually no induction was detected at 4 h (I–K, I1–K1), and a marked induction was seen at 8 h after kainate injection in wild type animals (L–N). This effect was much attenuated in transgenic animals, being absent (L1 and M1) or present at low levels in a single animal (N1). The arrows in B and E point to induction of caspase 3 mRNA in CA3 cells. The arrows in B1 and E1 point to the position of CA3 cells devoid of caspase 3 mRNA in hHSP27(18) animals. The arrow in L points to mHSP25 mRNA induction in hippocampus in wild-type animals at 8 h, which is not seen at4has shown by the arrow in I. The arrows in I1 and L1 point to the same region in hHSP27(18) animals, where no mHSP25 mRNA induction is seen. Scale bar, 2 mm.

 

Little induction of mHSP25 mRNA was seen at 4 h after kainate injection, in contrast to the levels of caspase 3 mRNA at this time point (Fig. 11, I, J, and K and Fig. 11, I1, J1, and K1) but became prominent at 8 h after kainate in all wild-type animals (Fig. 11, L, M, and N). By contrast, this effect was much attenuated in hHSP27(18) animals, being only detected at low levels in one animal (Fig. 11N1).

Semiquantitative analysis of caspase 3 mRNA levels in the CA3 region of hippocampus was carried out, in which sections were scored independently by three observers without knowledge of treatment conditions. The scoring scale ranged from 0 (no detectable mRNA (e.g. Fig. 11A)) to 3 (maximum signal intensity (e.g. Fig. 11G)). No caspase 3 mRNA was detected in vehicle-treated animals. The analysis yielded mean values for caspase 3 mRNA induction following kainate treatment in CA3 of 1.33 (range = 0–2, n = 6) in WT animals compared with 0.42 (range = 0–1.5, n = 6) in hHSP27(18) transgenic animals at 4 h after kainate injection. Similarly, at 8 h the mean value for wild-type animals was 2.5 (range = 1–3, n = 4) compared with 0.33 (range = 0–2, n = 9) for hHSP27(18) transgenic animals. This decrease in caspase 3 mRNA induction at 8 h after kainate injection was found to be significantly reduced (p < 0.003; Mann-Whitney U test) compared with control littermates.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In this study, we have generated three independent transgenic mouse lines, which express human HSP27 at high levels in a wide range of tissues, which include brain, spinal cord, heart, skeletal muscle, lung, liver, pancreas, and kidney. A detailed examination of the distribution patterns present in the brain confirmed the cellular localization within this tissue and provided a firm basis for the assay of the neuroprotective properties of HSP27 overexpression in vivo. In the brain, hHSP27 mRNA and protein was abundant within neurons of the cerebral cortex, hippocampus, striatum, cerebellum, and thalamic nuclei. In addition, glial expression was also evident. All three lines demonstrated a similar and robust pattern of expression of human HSP27, which was distinguishable from the expression of endogenous mouse HSP25 at the mRNA level by the use of selective oligonucleotide probes and both at the protein and mRNA level by use of an antibody or oligonucleotide probe specific to the HA tag sequence, which is contiguous with the hHSP27 cDNA sequence.

Our previous studies in cell culture indicated that HSP27 possessed a unique property among heat shock proteins tested to date of being able to protect neuronal cells in culture against apoptotic cell death (21). It was therefore of particular interest to use an in vivo model in which apoptotic cell death is known to occur as evidenced from morphological and molecular markers (42). Hence, we used the intraperitoneal administration of kainate to test the neuroprotective properties of hHSP27 overexpression in the transgenic lines generated. This model is well established in several laboratories and leads to a characteristic generation of seizures with induction of caspase 3 in the CA3 and CA1 regions of hippocampus (19, 49, 50), followed by the appearance of apoptotic changes in these regions and cell death (33, 43, 51). We therefore compared the behavioral responses to kainate injection with responses to vehicle injection in groups of two transgenic lines (lines 18 and 64). Morphological effects have been compared in parallel in line 18. A marked effect of neuroprotection was seen in both lines as evidenced from enhanced survival and significantly reduced seizure severity sustained over the major period of seizures (60–180 min).

The effect of HSP27 overexpression on cell death was examined at 7 days after kainate injection, where maximal cell death occurs in the CA3 region of the hippocampus. The severity of cell death usually ranges from 30 to 50% in the mouse (e.g. a 23% reduction in cell density following a dose of 34 mg/kg kainate). This level of cell loss between kainate and vehicle-treated animals was seen in the control littermates, being 33% (p < 0.05). In contrast, whereas cell density was similar in vehicle-treated transgenics compared with controls, no significant cell loss was detected in transgenic animals after kainate administration.

In order to control for strain differences in susceptibility to kainate, breeding at all generations was always with an F1 hybrid C57BL/CBA/Ca to maintain a hybrid genetic background. This strategy was adopted to avoid the marked differences that have been reported between inbred strains in behavioral tests involving kainate (e.g. Refs. 48 and 52). All tests were carried out between littermates that either carried the transgene (+ve) or lacked it (–ve), thus avoiding problems arising from the use of inbred strains. Thus, the reduced seizure susceptibility seen here in two independent transgenic lines is likely to have resulted from the overexpression of the human transgene.

We also show for the first time in this study the gross anatomical labeling pattern of induced endogenous mouse HSP25 mRNA in mice following kainic acid administration. Mouse HSP25 mRNA was predominantly localized to glial cells with modest labeling of neurons, particularly in the pyramidal cell layers of the hippocampus (data not shown), which reproduces the finding in rats (19). The distribution of mouse HSP25 mRNA was similar to that for GFAP mRNA as assessed on adjacent sections by in situ hybridization, although the upregulation of GFAP mRNA was more profound and widespread, in agreement with similar studies in rats (19). Up-regulation of GFAP has been described as a marker for neurotoxicity and aberrant neuronal activity (53, 54). The comparable pattern of expression and induction levels of mouse HSP25 mRNA and GFAP mRNA in both transgenic and wild-type mice in response to kainic acid would suggest that mice of both genotypes were subjected to a similar level of noxious stress.

The effect of overexpression of hHSP27 clearly showed a significant and rapid effect in the behavioral response to kainate injection, indicating an immediate suppression of the spread of the seizure activity. This may be due to an interaction of HSP27 with components of the excitatory signaling cascade involved in seizure propagation, which have not as yet been elucidated. HSP27 is known to be involved in apoptotic signaling cascades mediated by both caspase-dependent and Daxx components of Fas-mediated pathways (55), and these sites of action are likely to contribute to the longer term effects of HSP27 to reduce overall cell death.

Mechanism of Neuroprotection Mediated by hHSP27—In this study, we investigated whether one of the early markers of the cytochrome c-caspase-dependent pathway of apoptosis, caspase 3 induction, was affected in hHSP27 transgenic animals. This response is well known to be associated with kainate-induced cell death. We found a marked attenuation of caspase 3 mRNA induction in transgenic animals at both time points examined, which characterizes the initiation of this cascade and precedes other activation events such as the induction of endogenous mouse HSP25, which is delayed in onset compared with caspase 3 (Fig. 11). This is in keeping with the subsequent attenuated cell death seen in transgenic animals. These preliminary results therefore indicate that in vivo hHSP27 can moderate an early reaction in caspase 3-dependent apoptosis at a stage preceding caspase 3 induction, which in turn has a distinct time course compared with the delayed induction of the endogenous mouse HSP25 mRNA and its translation. The attenuated induction of mHSP25 may reflect a reduced caspase-dependent activation of the heat shock response but could also result from a direct down-regulation of heat shock factor activation of the transcription of heat shock proteins in the absence of denatured proteins.

This site of action of HSP27 is consistent with other studies where HSP27 has been shown to suppress cytochrome c-caspase 3-dependent apoptosis, affecting the release of cytochrome c (56), binding directly to cytochrome c, and thereby inhibiting subsequent apoptosome formation and preventing caspase 9 maturation (57). Recently, Benn et al. (58), using dissociated primary cultures of dorsal root ganglion cells to study neural growth factor withdrawal-induced apoptosis, showed that infection with herpes simplex virus vectors expressing the sense orientation of HSP27 rescued cells and that these cells were characterized by diffuse cytochrome c labeling in the cytoplasm but lacked activated caspase. This indicated that HSP27 action occurred downstream of cytochrome c release from mitochondria but prior to caspase 3 activation, which is consistent with the present findings. HSP27 appears able to act at multiple sites in this pathway, including more downstream events, through a direct interaction of HSP27 with caspase 3 processing, inhibiting cytochrome c-dependent apoptosis in 293T and L929 cells (59). The cell specificity of these actions of HSP27 remains to be elucidated in more intact systems. Events upstream of cytochrome c are also known to be affected by HSP27 and could contribute to protective effects, for example through the reduction of F-actin damage and through mobilization of members of the Bcl-2 family (56). The inhibitory effect of HSP27 is specific for cytochrome c-caspase-dependent apoptosis and does not affect the actions of apoptosis-inducing factor, which is also released from mitochondria during apoptosis. It has been demonstrated both in vivo and in vitro that large nonphosphorylated oligomers of HSP27 are the active form of the protein responsible for the caspase-dependent antiapoptotic effect of HSP27 (57).

In addition, HSP27 is known to inhibit Fas-mediated apoptosis (55), preventing c-Jun amino-terminal kinase 3 activation. Phosphorylation of HSP27 modulates activity by producing a large change in the supramolecular organization of the protein with a shift from oligomers to dimers. In Fas-mediated apoptosis, phosphorylated dimers of HSP27 interact with Daxx, a mediator of Fas-mediated apoptosis, preventing the interaction with Fas and Ask1 and blocking Daxx mediated apoptosis (55). The Daxx-dependent pathway is distinct from that mediated by FADD, which is not sensitive to HSP27. The involvement of this pathway in neuronal cell death in vivo remains to be elucidated.

It will also be important to determine the role of phosphorylation in mediating both the short and longer term effects of HSP27, which we have observed in vivo. An increase in phosphorylation is detected within minutes of a cellular stress, with the increased expression occurring after a few hours. The rapid stress-induced phosphorylation results from stimulation of the p38 mitogen-activated protein kinase cascade and leads to the phosphorylation of mammalian HSP27 at two or three serine residues by MAPKAP kinase 2/3. However, phosphorylation differentially affects the protective properties of HSP27. Thus, chaperone activity and the ability to block the mitochondrial pathway are inhibited by phosphorylation, whereas the ability to block Daxx-mediated apoptosis is stimulated by phosphorylation.

In contrast to the different effects of overexpression of HSP27 and HSP70 in neuronal cultures (21), a similar degree of protection has been demonstrated in cardiac cultures (25) and for cardiac tissue from transgenic animals overexpressing either HSP70 (60, 61) or HSP27 using the transgenic mice described here,2 indicating that both HSPs can interact with damaging oxidative cascades either through their protein chaperone properties or other mechanisms. It is already known that HSP27 increases glutathione (reduced form)-dependent chaperone activity against misfolded or oxidized proteins (62), which could contribute to protection against reactive oxygen species. Using in vivo models of cerebral ischemia, conflicting results have been obtained where protection has been reported by Rajdev et al. (26), whereas no significant difference in infarct size assessed at 24 h was found by Lee et al. (27). In the present study, a clear neuroprotective effect was seen with overexpression of HSP27 in vivo. These results provide further support for the idea that HSP27 is as important as HSP70 in the nervous system.

These studies demonstrate for the first time in vivo an important role for HSP27 in CNS tissue in response to apoptotic injury and provide support for the unique property of HSP27 among HSPs to protect neurons from apoptotic cell death. Recently, we demonstrated that intracerebral viral delivery of HSP27 reduced kainate-induced neuronal cell death in hippocampus in rats (63). Thus, HSP27 shows enormous potential as a target for neuroprotective intervention.


    FOOTNOTES
 
* This work was supported by the Wellcome Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Neuromuscular Diseases, Faculty of Medicine, Imperial College, Charing Cross Hospital, Fulham Palace Rd., London W6 8RF, United Kingdom. Tel.: 44-208-846-7052; Fax: 44-208-846-7099; E-mail: j.belleroche{at}imperial.ac.uk.

1 The abbreviations used are: HSP, heat shock protein; hHSP27, human HSP27; mHSP25, mouse HSP25; CNS, central nervous system; KA, kainic acid; PBS, phosphate-buffered saline; GFAP, glial fibrillary acidic protein; HA, hemagglutinin. Back

2 D. M. Yellon, D. S. Latchman, and J. de Belleroche, unpublished results. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Lindquist, S., and Craig, E. A. (1988) Annu. Rev. Genet. 22, 631–677[CrossRef][Medline] [Order article via Infotrieve]
  2. Ehrnsperger, M., Graber, S., Gaestel, M., and Buchner, J. (1997) EMBO J. 16, 221–229[Abstract/Free Full Text]
  3. Wagstaff, M. J., Collaco-Moraes, Y., Aspey, B. S., Coffin, R. S., Harrison, M. J., Latchman, D. S., and de Belleroche, J. (1996) Mol. Brain Res. 42, 236–244[CrossRef][Medline] [Order article via Infotrieve]
  4. Benjamin, I. J., and McMillan, D. R. (1998) Circ. Res. 83, 117–132[Abstract/Free Full Text]
  5. Sharp, F. R., Massa, S. M., and Swanson, R. A. (1999) Trends Neurosci. 22, 97–99[CrossRef][Medline] [Order article via Infotrieve]
  6. Feder, M. E., and Hofmann, G. E. (1999) Annu. Rev. Physiol. 61, 243–282[CrossRef][Medline] [Order article via Infotrieve]
  7. Christians, E. S., Yan, L. J., and Benjamin, I. J. (2002) Crit. Care Med. 30, S43–S50
  8. Lowenstein, D. H., Chan, P. H., and Miles, M. F. (1991) Neuron 7, 1053–1060[Medline] [Order article via Infotrieve]
  9. Rordorf, G., Koroshetz, W. J., and Bonventre, J. V. (1991) Neuron 7, 1043–1051[Medline] [Order article via Infotrieve]
  10. Amin, V., Cumming, D. V., Coffin, R. S., and Latchman, D. S. (1995) Neurosci. Lett. 200, 85–88[CrossRef][Medline] [Order article via Infotrieve]
  11. Cumming, D. V., Heads, R. J., Brand, N. J., Yellon, D. M., and Latchman, D. S. (1996) Basic Res. Cardiol. 91, 79–85[Medline] [Order article via Infotrieve]
  12. Uney, J. B., Kew, J. N., Staley, K., Tyers, P., and Sofroniew, M. V. (1993) FEBS Lett. 334, 313–316[CrossRef][Medline] [Order article via Infotrieve]
  13. Mailhos, C., Howard, M. K., and Latchman, D. S. (1994) J. Neurochem. 63, 1787–1795[Medline] [Order article via Infotrieve]
  14. Amin, V., Cumming D. V., and Latchman, D. S. (1996) Neurosci. Lett. 206, 45–48[CrossRef][Medline] [Order article via Infotrieve]
  15. Wyatt, S., Mailhos, C., and Latchman, D. S. (1996) Mol. Brain Res. 39, 52–56[Medline] [Order article via Infotrieve]
  16. Mestril, R., Chi, S. H., Sayen, M. R., O'Reilly, K., and Dillmann, W. H. (1994) J. Clin. Invest. 93, 759–767[Medline] [Order article via Infotrieve]
  17. Heads, R. J., Yellon, D. M., and Latchman, D. S. (1995) J. Mol. Cell Cardiol. 27, 1669–1678[Medline] [Order article via Infotrieve]
  18. Cumming, D. V., Heads, R. J., Watson, A., Latchman, D. S., and Yellon, D. M. (1996) J. Mol. Cell Cardiol. 28, 2343–2349[CrossRef][Medline] [Order article via Infotrieve]
  19. Akbar, M. T., Wells, D. J., Latchman D. S., and de Belleroche, J. (2001) Mol. Brain Res. 93, 148–163[Medline] [Order article via Infotrieve]
  20. Mailhos, C., Howard, M. K., and Latchman, D. S. (1993) Neuroscience 55, 621–627[CrossRef][Medline] [Order article via Infotrieve]
  21. Wagstaff, M. J., Collaco-Moraes, Y., Smith, J., de Belleroche, J. S., Coffin, R. S., and Latchman, D. S. (1999) J. Biol. Chem. 274, 5061–5069[Abstract/Free Full Text]
  22. Samali, A., and Cotter, T. G. (1996) Exp. Cell Res. 223, 163–170[CrossRef][Medline] [Order article via Infotrieve]
  23. Mehlen, P., Schulze-Osthoff, K., and Arrigo, A. P. (1996) J. Biol. Chem. 271, 16510–16514[Abstract/Free Full Text]
  24. Martin, J. L., Mestril, R., Hilal-Dandan, R., Brunton, L. L., and Dillmann, W. H. (1997) Circulation 96, 4343–4348[Abstract/Free Full Text]
  25. Brar, B. K., Stephanou, A., Wagstaff, M. J., Coffin, R. S., Marber, M. S., Engelmann, G., and Latchman, D. S. (1999) J. Mol. Cell Cardiol. 31, 135–146[CrossRef][Medline] [Order article via Infotrieve]
  26. Rajdev, S., Hara, K., Kokubo, Y., Mestril, R., Dillmann, W., Weinstein, P. R., and Sharp, F. R. (2000) Ann. Neurol. 47, 782–791[CrossRef][Medline] [Order article via Infotrieve]
  27. Lee, J. E., Yenari, M. A., Sun, G. H., Xu, L., Emond, M. R., Cheng, D., Steinberg, G. K., and Giffard, R. G. (2001) Exp. Neurol. 170, 129–139[CrossRef][Medline] [Order article via Infotrieve]
  28. Yenari, M. A., Giffard, R. G., Sapolsky, R. M., and Steinberg, G. K. (1999) Mol. Med. Today 5, 525–531[CrossRef][Medline] [Order article via Infotrieve]
  29. Ben-Ari, Y. (1985) Neuroscience 14, 375–403[CrossRef][Medline] [Order article via Infotrieve]
  30. Schwob, J. E., Fuller, T., Price, J. L., and Olney, J. W. (1980) Neuroscience 5, 991–1014[Medline] [Order article via Infotrieve]
  31. Pollard, H., Charriaut-Marlangue, C., Cantagrel, S., Represa, A., Robain, O., Moreau, J., and Ben-Ari, Y. (1994) Neuroscience 63, 7–18[CrossRef][Medline] [Order article via Infotrieve]
  32. Bengzon, J., Kokaia, Z., Elmér, E., Nanobashvili, A., Kokaia, M., and Lindvall, O. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10432–10437[Abstract/Free Full Text]
  33. Djebaïli, M., Lerner-Natoli, M., Pascale, M., Baille, V., Bockaert, J., and Rondouin, G. (2001) Mol. Brain Res. 93, 190–198[Medline] [Order article via Infotrieve]
  34. Puig, B., and Ferrer, I. (2001) Neurosci. Lett. 321, 182–186[CrossRef]
  35. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193–199[CrossRef][Medline] [Order article via Infotrieve]
  36. Racine, R. J. (1972) Electroencephalogr. Clin. Neurophysiol. 32, 281–294[CrossRef][Medline] [Order article via Infotrieve]
  37. Carper, S. W., Rocheleau, T. A., and Storm, F. K. (1990) Nucleic Acids Res. 18, 6457[Medline] [Order article via Infotrieve]
  38. Frohli, E., Aoyama, A., and Klemenz, R. (1993) Gene (Amst.) 128, 273–277[CrossRef][Medline] [Order article via Infotrieve]
  39. Lewis, S. A., Balcarek, J. M., Krek, V., Shelanski, M., and Cowan, N. J. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 2743–2746[Abstract]
  40. Juan, T. S., McNiece, I. K., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., and Fletcher, F. A. (1996) Oncogene 13, 749–755[Medline] [Order article via Infotrieve]
  41. Paxinos, G., and Franklin, K. B. J. (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd Ed., Academic Press, London, UK
  42. Yang, D. D., Kuan, C., Whitmarsh, A. J., Rincon, M., Zheng, T. S., Davis, R. J., Rakic, P., and Flavell, R. A. (1997) Nature 389, 865–870[CrossRef][Medline] [Order article via Infotrieve]
  43. Hu, R. Q., Koh, S., Torgerson, T., and Cole, A. J. (1998) Brain Res. 810, 229–240[CrossRef][Medline] [Order article via Infotrieve]
  44. Kitamura, Y., Ota, T., Matsouka, Y., Okazaki, M., Kakimura, J., Tooyama, I., Kimura, H., Shimohama, S., Gebicke-Haerter, P. J., Nomura, Y., and Taniguchi, T. (1998) Neurosci. Lett. 255, 57–60[CrossRef][Medline] [Order article via Infotrieve]
  45. Zhang, J., Lee, H., Agarwala, A., Lou, D. W., and Xu, M. (2001) Biochem. Biophys. Res. Commun. 285, 1143–1149[CrossRef][Medline] [Order article via Infotrieve]
  46. Chen, Z., Ljunggren, H., Bogdanovic, N., Nennesmo, I., Winblad, B., and Zhu, J. (2002) Brain Res. 931, 135–145[CrossRef][Medline] [Order article via Infotrieve]
  47. Kaasinen, K., Koistinaho, J., Alhonen, L., and Jänne, J. (2000) Eur. J. Neurosci. 12, 540–554[CrossRef][Medline] [Order article via Infotrieve]
  48. Royle, S. J., Collins, F. C., Rupniak, H. T., Barnes, J. C., and Anderson, R. (1999) Brain Res. 816, 337–349[CrossRef][Medline] [Order article via Infotrieve]
  49. Gillardon, F., Bottiger, B., Schmitz, B., Zimmermann, M., and Hossmann, K. A. (1997) Mol. Brain Res. 50, 16–22[Medline] [Order article via Infotrieve]
  50. Becker, A. J., Gillardon, F., Blumcke, I., Langendorfer, D., Beck, H., and Wiestler, O. D. (1999) Mol. Brain Res. 67, 172–176[CrossRef][Medline] [Order article via Infotrieve]
  51. Liu, H., Cao, Y., Basbaum, A. I., Mazarati, A. M., Sankar, R., and Wasterlain, C. G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12096–12101[Abstract/Free Full Text]
  52. Schauwecker, P. E., and Steward, O. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4103–4108[Abstract/Free Full Text]
  53. Steward, O., Torre, E. R., Tomasulo, R., and Lothman, E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6819–6823[Abstract]
  54. Torre, E. R., Lothman, E., and Steward, O. (1993) Brain Res. 631, 256–264[CrossRef][Medline] [Order article via Infotrieve]
  55. Charette, S. J., Lavoie, J. N., Lambert, H., and Landry, J. (2000) Mol. Cell. Biol. 20, 7602–7612[Abstract/Free Full Text]
  56. Paul, C., Manero, F., Gonin, S., Kretz-Remy, C., Virot, S., and Arrigo, A. P. (2002) Mol. Cell. Biol. 22, 816–834[Abstract/Free Full Text]
  57. Bruey, J. M., Ducasse, C., Bonniaud, P., Ravagnan, L., Susin, S. A., Diaz-Latoud, C., Gurbuxani, S., Arrigo, A. P., Kroemer, G., Solary, E., and Garrido, C. (2000) Nat. Cell Biol. 2, 645–652[CrossRef][Medline] [Order article via Infotrieve]
  58. Benn, S. G., Perrelet, D., Kato, A. C., Scholz, J., Decosterd, I., Mannion, R. J., Bakowska, C., and Woolf, C. J. (2002) Neuron 36, 45–56[Medline] [Order article via Infotrieve]
  59. Pandey, P., Farber, R., Nakazawa, A., Kumar, S., Bharti, A., Nalin, C., Weichselbaum, R., Kufe, D., and Kharbanda, S. (2000) Oncogene 19, 1975–1981[CrossRef][Medline] [Order article via Infotrieve]
  60. Marber, M. S., Mestril, R., Chi, S. H., Sayen, R., Yellon, D. M., and Dillman, W. H. (1995) J. Clin. Invest. 95, 1446–1456[Medline] [Order article via Infotrieve]
  61. Hutter, J. J., Mestril, R., Tam, E. K., Sievers, R. E., Dillmann, W. H., and Wolfe, C. L. (1996) Circulation 94, 1408–1411[Abstract/Free Full Text]
  62. Preville, X., Salvemini, F., Giraud, S., Chaufour, S., Paul, C., Stepien, G., Ursini, M. V., and Arrigo, A. P. (1999) Exp. Cell Res. 247, 61–78[CrossRef][Medline] [Order article via Infotrieve]
  63. Kalwy, S. A., Akbar, M. T., Coffin, R. S., de Belleroche, J., and Latchman, D. S. (2003) Mol. Brain Res. 111, 91–103[Medline] [Order article via Infotrieve]